

# Trichotillomania—psychopathological correlates and associations with health-related quality of life in a large sample

## Original Research

**Cite this article:** Bezerra AP, Machado MO, Maes M, Marazziti D, Nunes-Neto PR, Solmi M, Firth J, Husain MI, Brunoni AR, Kurdyak P, Smith L, Alavi A, Piguet V, and Carvalho AF (2021). Trichotillomania—psychopathological correlates and associations with health-related quality of life in a large sample. *CNS Spectrums* 26(3), 282–289. <https://doi.org/10.1017/S109285292000111X>

Received: 20 November 2019

Accepted: 09 January 2020

### Key words:

Trichotillomania; behavioral addictions; quality of life; comorbidities; psychiatry


### Author for correspondence:

Andre F. Carvalho, MD

Email: [andre.carvalho@camh.ca](mailto:andre.carvalho@camh.ca);

[andrefc7@hotmail.com](mailto:andrefc7@hotmail.com)

Andre P. Bezerra and Myrela O. Machado contributed equally to this manuscript.

Andre P. Bezerra<sup>1</sup>, Myrela O. Machado<sup>2</sup>, Michel Maes<sup>3,4</sup> , Donatella Marazziti<sup>5</sup> , Paulo R. Nunes-Neto<sup>6</sup>, Marco Solmi<sup>7,8</sup>, Joseph Firth<sup>9,10</sup>, M. Ishrat Husain<sup>11,12</sup>, Andre R. Brunoni<sup>13,14,15</sup>, Paul Kurdyak<sup>11,12,16</sup>, Lee Smith<sup>17</sup>, Afsaneh Alavi<sup>2,18</sup>, Vincent Piguet<sup>2,18,19</sup> and André F. Carvalho<sup>11,12</sup> 

<sup>1</sup>Unichristus Medical School, Fortaleza, Brazil, <sup>2</sup>Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada, <sup>3</sup>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, <sup>4</sup>IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, Victoria, Australia, <sup>5</sup>Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Pisa, Italy, <sup>6</sup>Department of Clinical Medicine, Federal University of Ceara, Fortaleza, Brazil, <sup>7</sup>Department of Neurosciences, University of Padova, Padova, Italy, <sup>8</sup>Padova Neuroscience Center, University of Padua, Padua, Italy, <sup>9</sup>NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia, <sup>10</sup>Division of Psychology and Mental Health, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, <sup>11</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada, <sup>12</sup>Centre for Addiction & Mental Health (CAMH), Toronto, Ontario, Canada, <sup>13</sup>Service of Interdisciplinary Neuromodulation, Laboratory of Neurosciences (LIM-27) National Institute of Biomarkers in Neuropsychiatry (INBioN), Institute of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil, <sup>14</sup>National Institute of Biomarkers in Neuropsychiatry (INBioN), Institute of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil, <sup>15</sup>Department of Clinical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil, <sup>16</sup>Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada, <sup>17</sup>Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, United Kingdom, <sup>18</sup>Department of Medicine (Dermatology), University of Toronto, Toronto, Ontario, Canada, and <sup>19</sup>Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

## Abstract

**Background.** Relatively few studies have assessed the prevalence, correlates, and independent impact on quality of life (QoL) of trichotillomania (TTM) in large samples.

**Methods.** Consecutive participants (N = 7639) were recruited from a cross-sectional web-based study. Sociodemographic data were collected and several validated self-reported mental health measures were completed (Minnesota Impulsive Disorders Interview, Hypomania checklist, Fagerström Test for Nicotine Dependence, Alcohol Use Disorders Identification Test, Early Trauma Inventory Self Report–Short Form, and the Symptom Checklist-90–Revised Inventory). Health-related QoL was assessed with the World Health Organization QoL abbreviated scale (WHOQOL-Bref). Multivariable models adjusted associations to potential confounders.

**Results.** The sample was predominantly composed of young females (71.3%; mean age: 27.2 ± 7.9 years). The prevalence of probable TTM was 1.4% (95% confidence intervals [CI]: 1.2–1.7), and was more common among females. Participants with probable TTM had a greater likelihood of having co-occurring probable depression (adjusted odds ratio [ORadj] = 1.744; 95% CI: 1.187–2.560), tobacco (ORadj = 2.250; 95% CI: 1.191–4.250), and alcohol (ORadj = 1.751; 95% CI: 1.169–2.621) use disorders. Probable TTM was also independently associated with suicidal ideation (ORadj = 1.917; 95% CI: 1.224–3.003) and exposure to childhood sexual abuse (ORadj = 1.221; 95% CI: 1.098–1.358). In addition, a positive screen for TTM had more impaired physical and mental QoL.

**Conclusions.** TTM was associated with a positive screen for several psychiatric comorbidities as well as impaired physical and psychological QoL. Efforts towards the recognition and treatment of TTM across psycho-dermatology services are warranted.

## Introduction

Trichotillomania (TTM) or hair-pulling disorder is classified as an obsessive-compulsive spectrum disorder according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).<sup>1</sup> This chronic condition is characterized by urges to remove one's body hair leading to hair loss. The most common sites reported are the scalp, eyelashes, eyebrows, beard, and pubic hair.<sup>2</sup> Those suffering from TTM often report feelings of unattractiveness, humiliation, and low self-confidence.<sup>3</sup>

Patients with TTM most often seek care at dermatology and psychodermatology services, and the management of this disorder is a clinical challenge.<sup>2,4</sup> Relatively, few studies on the

epidemiology of TTM have been conducted, and the exact prevalence of this disorder in the community remains unclear but appears to range from 1% to 3% with a marked predominance among females.<sup>5</sup> Most studies have been conducted in clinical settings or otherwise have enrolled convenience samples (eg, university students), and suggest that TTM may be associated with several psychiatric comorbidities including depression and anxiety.<sup>2,6</sup> In addition, the independent impact of TTM on health-related quality of life (QoL) has been a matter of debate with a study reporting no impact of TTM on QoL relative to healthy controls,<sup>7</sup> while two other studies verified that people with TTM may have more impaired QoL than nonpsychiatric controls.<sup>8,9</sup> Moreover, the impact of TTM on different QoL domains remains largely unknown.

The present study aims to: (a) investigate the prevalence of TTM in a large Brazilian sample; (b) provide an extensive characterization of sociodemographic and psychopathological correlates of TTM; and (c) determine the independent impact of TTM on QoL dimensions.

## Methods

### Study design and participants

Consecutive participants (N = 9603) were recruited from a large online survey in Brazil, which is a project that aims to investigate the prevalence and correlates of several diseases and psychopathological conditions using validated self-reported measures. Methodological details of this large cross-sectional study are provided elsewhere.<sup>10–12</sup> Online surveys have been previously adopted to estimate the prevalence and correlates of psychiatric conditions.<sup>13,14</sup> To access this survey, participants had to be 18 years old or older.

Potential participants were all individuals living in Brazil who had Internet access. No incentives were granted for participation in this survey. Numerous questions to assess attention/validation were employed throughout to assess data quality. Participants who did not provide valid responses to these questions were excluded from analyses.

From the initial sample, 7639 participants were eligible (ie, provided correct responses to the validation/attention questions) and were included in final analyses (response rate: 79.7%). There were no significant differences in background sociodemographic variables between participants who were eligible compared to those excluded from analyses (data available upon request).

This online survey collected sociodemographic data and included several validated self-reported instruments (see below).

### Measures

#### Minnesota Impulsive Disorders Interview (MIDI)

The MIDI is a 36-item semi-structured interview that screens for several disorders including pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior. The presence of each disorder is initially assessed with a general question, which if answered affirmatively, allows the interviewer to respond to other questions. The TTM module comprises a 6-item tool and a positive screening is established if all questions are answered affirmatively.<sup>15</sup> This 6-item questionnaire was translated to Brazilian Portuguese, and then back translated into English. Two bilingual authors (M.O.M. and A.F.C.) compared the back-translated version to the original version of the MIDI, and modifications to ensure semantic equivalence were performed. This Brazilian Portuguese version of the

MIDI was tested in a pilot sample of five outpatients of the psychiatry service of the Walter Cantídio University Hospital, who reported no difficulties in understanding any of its items. Six experts in the field of obsessive-compulsive and related disorders provided a qualitative assessment of the content validity of the TTM module of the MIDI. In brief, experts were asked to provide comments on each item regarding grammar, wording, scaling, and item allocation, as well as the accuracy, clarity, style, and relevance of the translation. We calculated the content validity index (CVI) as described in detail in previous studies.<sup>16,17</sup> To compute the CVI, members of the expert panel were asked to rate each MIDI item in terms of relevance, clarity, and simplicity on a Likert scale ranging from 1 to 4. The CVI for each item was computed as the number of experts assigning a rate of 3 or 4 to the item divided by the total number of experts. The overall TTM-MIDI CVI value was obtained by averaging all items. The overall CVI of the Brazilian Portuguese version of the TTM-MIDI was 0.92 (range for individual items: 0.50–1.00), thus supporting its content validity. The final Brazilian Portuguese version of the TTM-MIDI is available upon request to the corresponding author of this manuscript. The MIDI was considered a positive screen if all questions were answered affirmatively. The Cronbach's alpha of MIDI in the current sample was 0.83 (95% confidence interval [CI]: 0.82–0.84) indicating adequate internal consistency reliability.

#### Hypomania checklist (HCL-32)

The HCL-32 consists of 32 yes/no questions and investigates the presence of hypomanic symptoms.<sup>18</sup> It also includes eight severity and functional impact items related to the duration of episodes and to positive and negative consequences over different areas of functioning. We used the validated Brazilian Portuguese version of the HCL-32 with the recommended cutoff of 19 for nonclinical samples.<sup>19</sup> For a positive screening for a bipolar spectrum disorder (BD), participants had to endorse impairment in at least one area of functioning due to the presence of hypomanic symptoms. A previous meta-analysis supports the accuracy of the HCL-32 for the screening of BD.<sup>20</sup> In the current sample, the reliability of the HCL-32 instrument was adequate (Cronbach's alpha = 0.82; 95% CI: 0.81–0.82).

#### Patient Health Questionnaire 9 (PHQ-9)

We used the validated Brazilian Portuguese version of the PHQ-9 to assess severity of depressive symptoms.<sup>21,22</sup> A positive screening for major depressive disorder (MDD) was established through a previously reported algorithm.<sup>21</sup> In addition, we used question 9 of the PHQ-9 to screen for the presence of suicidal ideation.<sup>23</sup> The Cronbach's alpha of the PHQ-9 in the current sample was 0.89 (95% CI: 0.88–0.89).

#### Fagerström Test for Nicotine Dependence (FTND)

DSM-IV nicotine dependence was assessed using the validated Brazilian Portuguese version of the FTND,<sup>24</sup> a 6-item self-report questionnaire with scores ranging from 0 to 10.<sup>25</sup> A cut-off score of 4 on the FTND was considered as indicative of nicotine dependence in the current study. The Cronbach's alpha of the FTND in the current sample was 0.74 (95% CI: 0.71–0.76).

#### Alcohol Use Disorders Identification Test (AUDIT)

Alcohol use disorder was assessed using the validated Brazilian Portuguese version of the AUDIT,<sup>26</sup> a 10-item self-report questionnaire developed by the World Health Organization (WHO) to screen for the presence of alcoholism.<sup>27</sup> A score  $\geq 8$  was considered indicative of the presence of an alcohol use disorder.<sup>27</sup> In the

current study, the AUDIT had adequate reliability (Cronbach's alpha = 0.83; 95% CI: 0.82-0.83).

#### Early Trauma Inventory Self Report–Short Form (ETISR-SF)

Exposure to early trauma was assessed using the validated Brazilian Portuguese version of the ETISR-SF.<sup>28</sup> This is self-report inventory comprises 27 items grouped into 4 dimensions (general trauma, physical abuse, emotional abuse, and sexual abuse).<sup>29</sup> The ETISR-SF exhibited adequate internal consistency reliability in the current sample (Cronbach's alpha = 0.86; 95% CI: 0.86-0.87).

#### Symptom Checklist-90–Revised Inventory (SCL-90R)

Psychopathological dimensions were assessed using the Brazilian Portuguese version of the Symptom Checklist-90–Revised Inventory (SCL-90R).<sup>30,31</sup> This is a 90-item, 5-point, Likert-type scale, which assesses several psychopathological dimensions: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. In this study, Cronbach's alpha for the SCL-90R dimensions ranged from 0.79 (95% CI: 0.79-0.80) for paranoid ideation to 0.92 (95% CI: 0.91-0.92) for the depression dimension.

#### World Health Organization QoL instrument—abbreviated version (WHOQOL-BREF)

We used the validated Brazilian Portuguese version of the WHOQOL-BREF to assess QoL.<sup>32</sup> This scale consists of 26 items assessing QoL in four dimensions: physical, psychological, social, and environment QoL.<sup>33</sup> Each item is rated on a 5-point, Likert-type scale, and scores are transformed on a scale from 0 to 100, with higher scores indicating higher QoL. Cronbach's alpha values were 0.80 (95% CI: 0.80-0.81), 0.83 (95% CI: 0.82-0.84), 0.68 (95% CI: 0.67-0.70), and 0.79 (95% CI: 0.78-0.79) for the physical, psychological, social, and environment domains of the WHOQOL-BREF, respectively.

#### Ethics

The website ([www.temperamentoesaudemental.org](http://www.temperamentoesaudemental.org)) provided an encrypted and confidential source for data collection. The research ethics committee of the Walter Cantídio University Hospital approved all research procedures under the protocol number 1.058.252. To access the surveys, participants were required to sign a digital informed consent form.

#### Statistical analysis

Sociodemographic and psychopathological variables were compared between participants with TTM and those without TTM. Normally distributed continuous variables were compared using Student's *t*-test for independent samples. Categorical variables were compared using Pearson's chi-square ( $\chi^2$ ) or Fisher's exact tests as appropriate. Different logistic regression models were performed with a positive screen for TTM as the dependent variable, and a positive screen for MDD, BD, alcohol or tobacco use disorder, trauma, suicidal ideation, as well as SCL-90R psychopathological domain scores as independent variables. For the association of TTM and psychopathological dimensions, the scores of each SCL-90R domain were entered as continuous independent variables in the model. For the association of TTM and suicidal ideation, the PHQ-9 question 9 response was entered in the model as a categorical variable. For the associations between

TTM and trauma domains, the scores of each individual ETISR-SF domain were entered as continuous independent variables. All other independent variables were categorical. All multivariable models were adjusted for age, sex, occupation, previous use of psychotropic drugs, education level, ethnicity, and other background variables as indicated. Multivariable models that assessed the association of probable TTM and suicidal ideation as well as exposure to early life trauma additionally controlled for the presence of a positive screening for MDD, BD, nicotine dependence, and alcohol dependence.

Separate analysis of covariance (ANCOVA) models were built to assess independent associations of probable TTM (predictor variable) and each WHOQOL-BREF domain (dependent variables). Each model was adjusted by age, sex, occupation, family history of mental disorders, previous use of psychotropic drugs, education level, ethnicity, marital status, gross monthly income, presence of a positive screening for a major depressive episode, bipolar spectrum disorder, a positive screen for suicidal ideation, nicotine dependence, and alcoholism (reflected as a positive screening based on the AUDIT). In addition, we estimated effect sizes of statistically significant associations of probable TTM and QoL domains with partial eta squared ( $\eta_p^2$ ); effect sizes were regarded as small, medium, and large when  $0.01 < \eta_p^2 < 0.06$ ,  $0.06 \leq \eta_p^2 < 0.14$ , and  $\eta_p^2 \geq 0.14$ , respectively.<sup>34</sup>

The internal consistency reliability of each instrument used in the current study was estimated through Cronbach's alpha coefficients (and 95% CIs). Statistical significance was set at an alpha level of 0.05. All statistical analyses were performed using SPSS (IBM, Armonk, NY) version 22.0 for Windows.

#### Results

Table 1 summarizes the sociodemographic variables of the sample, which was predominantly comprised of women (71.3%), with a mean age of  $27.2 \pm 7.9$  years. The prevalence of probable TTM was 1.4% (95% CI: 1.2-1.7). In addition, the prevalence of probable TTM was significantly higher among women with a total prevalence of 1.63% in women, compared to 0.95% in men ( $P = 0.025$ ). TTM was not associated with other sociodemographic variables.

#### Psychopathological Correlates of TTM

Associations of mental health correlates and a positive screen for TTM are presented in Table 2. The presence of probable TTM was independently associated with a positive screen for MDD, tobacco use disorder, and alcohol use disorder. Participants with probable TTM were also more likely to exhibit suicidal ideation.

Finally, TTM was independently associated with exposure to childhood sexual abuse, but not with general traumatic experiences, psychological abuse, and physical abuse.

#### Correlation between probable TTM and QoL domains

Probable TTM was independently associated with impaired physical and psychological QoL (Figure 1). However, the presence of probable TTM was not associated with social and environment QoL. All ANCOVA models were statistically significant (adjusted  $R^2$  values ranged from 0.172 to 0.444). Effect sizes for the adjusted associations of probable TTM and physical ( $\eta_p^2 = 0.33$ ) and psychological ( $\eta_p^2 = 0.44$ ) QoL domains were large.

**Table 1.** Sociodemographic Characteristics of Study Participants. Bold values:  $P < 0.05$ .

Variable	Total (N = 7639)	Trichotillomania (N = 110)	No Trichotillomania (N = 7529)	P Value
Age, years (mean $\pm$ SD)	27.2 $\pm$ 7.9	25.6 $\pm$ 6.8	27.2 $\pm$ 7.9	<b>.041<sup>a</sup></b>
Sex				
Female	5446 (71.3)	89 (80.9)*	5357 (71.2)**	<b>.025<sup>b</sup></b>
Male	2193 (28.7)	21 (19.1)**	2172 (28.8)*	
Occupation				
Employed	2768 (36.2)	42 (39.2)	2726 (35.0)	.992 <sup>c</sup>
Unemployed	2672 (35)	39 (35.5)	2633 (35.0)	
Housewife	368 (4.8)	5 (4.5)	363 (4.8)	
Retired	36 (0.5)	0	36 (0.5)	
Self-employed	757 (9.9)	9 (8.2)	748 (9.9)	
Other status	1038 (13.6)	15 (13.6)	1023 (13.6)	
Family history of mental disorders				
Yes	3335 (43.7)	52 (47.3)	3283 (43.6)	.660 <sup>c</sup>
No	4046 (53.0)	54 (49.1)	3992 (53.0)	
Do not know (adopted child)	258 (3.4)	4 (3.6)	254 (3.4)	
Previous use of psychotropic drugs N (%)				
Yes, not currently	1177 (15.4)	24 (21.8)	1153 (15.3)	.167 <sup>b</sup>
Yes, currently	808 (10.6)	10 (9.1)	798 (10.6)	
No	5654 (74.0)	76 (69.1)	5578 (74.1)	
Daily smoking for the last 12 months N (%)				
1129 (14.8)	21 (19.1)	1108 (14.7)	.199	
Years of education N (%)				
Less than fundamental	86 (1.1)	3 (2.7)	83 (1.1)	.266 <sup>c</sup>
Fundamental school	483 (6.3)	6 (5.5)	477 (6.3)	
High school	4721 (61.8)	72 (65.5)	4649 (61.7)	
Superior	2349 (30.8)	29 (26.4)	2320 (30.8)	
Ethnicity N (%)				
Caucasian	3459 (45.3)	49 (44.5)	3410 (45.3)	.702 <sup>c</sup>
African American	773 (10.1)	9 (8.2)	764 (10.1)	
Mulatto <sup>d</sup>	2958 (38.7)	43 (39.1)	2915 (38.7)	
Asian	87 (1.1)	1 (0.9)	86 (1.1)	
Other	362 (4.7)	8 (7.3)	354 (4.7)	
Marital status N (%)				
Single	4849 (63.5)	70 (63.6)	4779 (63.5)	.191 <sup>b</sup>
Married	1021 (13.4)	10 (9.1)	1011 (13.4)	
Stable union	787 (10.3)	17 (15.5)	770 (10.2)	
Divorced/widow	481 (6.3)	4 (3.6)	477 (6.3)	
Other	501 (6.6)	9 (8.2)	492 (6.5)	
Religion N (%)				
Catholic	2305 (30.2)	34 (30.9)	2271 (30.2)	.670 <sup>b</sup>
Evangelical (Protestant)	1864 (24.2)	24 (21.8)	1840 (24.4)	
Spiritist	619 (8.1)	13 (1.4)	606 (8.0)	
Agnostic	1203 (15.7)	17 (15.3)	1186 (15.8)	
Other	1648 (21.8)	22 (20.0)	1626 (21.6)	

Table 1. Continued.

Variable	Total (N = 7639)	Trichotillomania (N = 110)	No Trichotillomania (N = 7529)	P Value
Gross monthly income N (%)				
Less than US\$ 310.00	2806 (36.7)	42 (38.2)	2764 (36.7)	.964 <sup>b</sup>
Between US\$ 310.00 and US\$ 931.00	2549 (33.4)	33 (30.0)	2516 (33.4)	
Between US\$ 931.00 and US\$ 1863.00	736 (9.6)	11 (10.0)	725 (9.6)	
More than US\$ 1863.00	382 (0.5)	6 (0.08)	376 (5.0)	
Unknown/not informed	1166 (15.3)	18 (16.4)	1148 (15.2)	
Positive screening for major depressive episode N (%)	2201 (28.8)	47 (42.7)*	2154 (28.6)**	<.001 <sup>b</sup>
Positive screening for bipolar spectrum disorder N (%)	572 (7.6)	13 (11.8)	585 (7.7)	.098 <sup>b</sup>
Positive screening for nicotine dependence N (%)	459 (6.0)	12 (10.9)*	447 (5.9)**	.029 <sup>b</sup>
Positive screening for alcohol abuse N (%)	1759 (23.0)	37 (33.6)*	1722 (22.9)**	.008 <sup>b</sup>
Positive screening for suicidal ideation N (%)	1909 (25.0)	49 (44.5)*	1860 (24.7)**	<.001 <sup>b</sup>

<sup>a</sup>Independent samples Student's *t* test.

<sup>b</sup>Pearson's chi-square test.

<sup>c</sup>Fisher's exact test.

<sup>d</sup>Refers to an ethnic group of mixed White and Black ancestry.

\*Observed was higher than expected in this cell (adjusted residual >2).

\*\*Observed was lower than expected in this cell (adjusted residual <-2).

Table 2. Association of Mental Health Correlates and Trichotillomania.

Variable	Unadjusted		Adjusted <sup>a</sup>	
	OR (95% CI)	P Value <sup>b</sup>	OR (95% CI)	P Value <sup>b</sup>
MDD positive screening (PHQ-9)	1.861 (1.274-2.719)	.001	1.744 (1.187-2.560)	<.005
BD positive screening (HCL-32)	1.630 (0.915-2.903)	.098	1.616 (0.896-2.913)	.111
Tobacco use disorder (FTND)	1.940 (1.067-3.529)	.029	2.250 (1.191-4.250)	.012
Alcohol use disorder (AUDIT)	1.709 (1.149-2.541)	.008	1.751 (1.169-2.621)	.007
Suicide <sup>c</sup>				
Suicidal ideation (PHQ-9)	2.448 (1.678-3.571)	<.001	1.917 (1.224-3.003)	.004
Suicidal symptoms severity (RASS)	1.005 (0.998-1.012)	.140	1.002 (0.995-1.009)	.540
Psychopathological dimensions (SCL-90) <sup>d</sup>				
Somatization	1.221 (0.850-1.756)	.280	1.181 (0.811-1.719)	.385
Obsessive Compulsive	1.230 (0.836-1.810)	.294	1.217 (0.826-1.792)	.321
Interpersonal sensitivity	0.977 (0.656-1.455)	.909	0.918 (0.614-1.373)	.678
Depression	0.987 (0.647-1.506)	.950	0.966 (0.630-1.482)	.874
Anxiety	0.797 (0.469-1.356)	.404	0.804 (0.471-1.372)	.425
Hostility	1.097 (0.803-1.499)	.561	1.084 (0.791-1.484)	.616
Phobic anxiety	1.135 (0.818-1.576)	.447	1.115 (0.802-1.550)	.517
Paranoid ideation	0.842 (0.577-1.228)	.371	0.910 (0.619-1.339)	.633
Psychoticism	1.496 (0.947-2.363)	.084	1.536 (0.964-2.446)	.071
Trauma (ETISR-SF) <sup>c,d</sup>				
General trauma	0.970 (0.882-1.067)	.534	0.970 (0.880-1.070)	.546
Physical abuse	1.055 (0.912-1.220)	.475	1.074 (0.922-1.251)	.358
Psychological abuse	1.060 (0.945-1.189)	.320	1.027 (0.912-1.157)	.657
Sexual abuse	1.252 (1.128-1.389)	<.001	1.221 (1.098-1.358)	<.001

Abbreviations: AUDIT, Alcohol Use Disorders Identification Test; BD, bipolar disorder; CI, confidence intervals; ETISR-SF, Early Trauma Inventory Self Report—Short Form; FTND, Fagerström Test for Nicotine Dependence; HCL-32, Hypomania Checklist; MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire 9; RASS, Risk Assessment Suicidality Scale; SCL-90, Symptom Checklist-90.


<sup>a</sup>Adjusted for age, gender, education, ethnicity, occupation, and history of psychotropic medication use.

<sup>b</sup>Bold values are significant at an  $\alpha$  level of 0.05 after Bonferroni correction for multiple comparisons

<sup>c</sup>Adjusted for a positive screening for MDD or BD, and tobacco or alcohol use disorder.

<sup>d</sup>Per unit increase in dimension score.





**Figure 1.** Associations of probable trichotillomania and physical, psychological, social, and environment quality of life (QoL) as assessed with the World Health Organization QoL abbreviated scale (WHOQOL-BREF). \* $P < .05$  (separate ANCOVA models adjusted for sociodemographic and psychopathological variables; see the “Methods” section for further details). Scores of WHOQOL-BREF domains are presented as means and 95% confidence intervals.

## Discussion

To the best of our knowledge, the current study is the largest cross-sectional survey investigating the prevalence and correlates of TTM. Previous studies often evaluated TTM only in children and young adults, with a reported lifetime prevalence ranging between 0.6% and 2.4%, and a range point prevalence between 0.5% and 1.2%.<sup>6,35,36</sup> There is a recent online survey study in a nonclinical sample that presented a point prevalence of 2%.<sup>37</sup> Those data are in accordance with our findings which found a point prevalence of probable TTM of 1.4% (95% CI: 1.2-1.7). Previous studies have also reported a greater prevalence of TTM among women, with a female to male ratio ranging between 1.5:1 and 7:1.<sup>6,35,36,38</sup> Our results are consistent with those findings, as 80.9% of the participants who had a positive screening for trichotillomania were females.

The results of the current study show that probable TTM was independently associated with a positive screen for MDD, nicotine and alcohol dependence. These findings are consistent with previous studies conducted in clinical samples. For instance, although the prevalence of MDD has varied across studies (from 12.5% to 48.0%),<sup>8,39,40</sup> evidence overall suggests that depression is more common amongst patients with TTM than in the general population. These findings have clinical relevance, and physicians assessing TTM should consider those co-occurring mental health condition to provide a comprehensive treatment plan to those patients.

The independent associations with probable TTM and nicotine and alcohol use disorders merit further discussion. Both nicotine and alcohol use disorders are characterized by the repetitive engagement in behaviors that are rewarding, loss of control (spiraling engagement over time), as well as persistence despite detrimental consequences to one’s life and overall functioning.<sup>41</sup> Interestingly, the emerging concept of behavioral addictions, indicates that several habit-related disorders may share features with addictions. For example, TTM and skin picking disorder may present phenomenological similarities with substance use disorders. For example, TTM is associated with impaired control, functional impairment, and persisting engagement in the dysfunctional behaviors despite negative consequences.<sup>41,42</sup> It was suggested that glutamatergic modulation of dopaminergic tone in the nucleus accumbens, and possibly

the prefrontal cortex, could be a common mechanism underlying both behavioral addictions (eg, TTM) and substance use disorders.<sup>41,43,44</sup> To the best of our knowledge, no previous studies assessed the associations of TTM and alcohol or nicotine use disorders in large population samples. Thus, our epidemiological findings appear to be consistent with this hypothesis.

Suicidal ideation was also independently associated with probable TTM. To our knowledge, no previous studies assessed the association of suicidal ideation among people with TTM. Interestingly, this association survived adjustment to meaningful confounders such as the presence of co-occurring mental disorders which are known risk factors for suicide (eg, depression and alcohol use disorder).<sup>45</sup> Clearly, this clinically relevant finding deserves independent replication.

In our survey, there was an independent association of exposure to sexual abuse in childhood and probable TTM. In the clinical study conducted by Ozten et al.,<sup>46</sup> patients with TTM were more likely than healthy controls to endorse previous exposure to traumatic events in childhood, such as neglect, abuse, extreme violence as well as sexual harassment and intercourse. Our findings also support those of Gershuny et al.,<sup>47</sup> who found that the prevalence of post-traumatic stress disorder among patients with TTM may be higher than in the general population. Several studies have suggested that trauma may play a role in the etiology of TTM and it has been hypothesized that TTM may develop in some traumatized individuals as a means to cope with those overwhelming experiences.<sup>46-48</sup>

Probable TTM was also independently associated with impaired physical and psychological QoL. Previous studies presented discrepant findings,<sup>7-9</sup> which may at least in part reflect the enrollment of participants from different settings since our study enrolled participants with probable TTM from a nonclinical setting, whilst previous studies were conducted in clinical settings. Furthermore, previous studies enrolled relatively small samples.

## Strengths and limitations

Our findings should be interpreted under the light of certain limitations. First, we enrolled an online sample with a

predominance of young women that may not be representative of the Brazilian general population. Second, we did not use validated structured diagnostic interviews to confirm diagnoses although we did use validated self-reporting measures and all instruments applied in the current study exhibited adequate internal consistency reliabilities. Third, an online project such as ours may have attracted a higher proportion of participants with mental disorders, thereby overestimating the prevalence of TTM. Finally, the cross-sectional design of our study limits us from drawing any causal inferences from the results. Conversely, the large sample size and use of validated assessment tools and use of attention/validation questions are strengths of the current study. Furthermore, anonymous participation via the internet provides a setting with low desirability bias when responding to these assessment tools. This is especially relevant in TTM, since previous research shows that patients with such conditions experience a long delay from onset of symptoms to treatment initiation, partly due to the shame individuals may experience as a consequence of their symptoms.<sup>49</sup>

## Conclusion

TTM appears to be a prevalent condition associated with psychiatric comorbidities. The presence of probable TTM was also independently associated with exposure to childhood sexual abuse and suicidal ideation. In addition, the presence of probable TTM had a strong independent and detrimental impact on physical and psychological QoL. Our findings highlight that the early recognition and management of TTM (and associated comorbidities), particularly in at-risk settings (eg, dermatological clinics), is warranted. The design of further large-scale epidemiological studies is a necessary next step to replicate/refute our findings.

**Funding.** This study was financially supported by the National Council for Scientific and Technological Development (Brazil; grant number: 447414/2014-3).

**Disclosures.** Andre Bezerra, Myrela Machado, Michael Maes, Donatella Marazziti, Paulo R. Nunes-Neto, Marco Solmi, Joseph Firth, M. Ishrat Husain, Andre R. Brunoni, Paul Kurdyak, Lee Smith, and Andre F. Carvalho have nothing to disclose. Vincent Piguet received grants and personal fees from AbbVie during the conduct of the study; educational grants in his role as Department Division Director, Dermatology, at the University of Toronto from AbbVie, Celgene, Janssen, Naois, Lilly, Sanofi, and Valeant; and nonfinancial support from La Roche-Posay. Vincent Piguet is also serving as an advisor for AbbVie. Afsaneh Alavi has been advisor and investigator for Abbvie, Janssen, InflaRx, Novartis and Incyte and received educational grants from Abbvie.

## References

1. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Washington, DC: American Psychiatric Pub; 2013.
2. Grant JE, Chamberlain SR. Trichotillomania. *Am J Psychiatry*. 2016;**173**(9):868–874.
3. Bottesi G, Cerea S, Razzetti E, Sica C, Frost RO, Ghisi M. Investigation of the phenomenological and psychopathological features of Trichotillomania in an Italian Sample. *Front Psychol*. 2016;**7**:256.
4. Carr JM, Mortimer H, Martin K, Kaur M, Goulding JMR. A retrospective review of 12 patients with trichotillomania treated in a psychodermatology service. *Clin Exp Dermatol*. 2019;**44**(6):658–660.
5. Panza KE, Pittenger C, Bloch MH. Age and gender correlates of pulling in pediatric trichotillomania. *J Am Acad Child Adolesc Psychiatry*. 2013;**52**(3):241–249.
6. Grzesiak M, Reich A, Szepietowski JC, Hadrys T, Pacan P. Trichotillomania among young adults: prevalence and comorbidity. *Acta Dermato-Venereol*. 2017;**97**(4):509–512.
7. Keuthen NJ DD, Franklin ME, Bohne A, Loh R, Levy J, Deckersbach T. Quality of life and functional impairment in individuals with trichotillomania. *J Appl Res*. 2004;**4**:186–197.
8. Houghton DC, Maas J, Twohig MP, et al. Comorbidity and quality of life in adults with hair pulling disorder. *Psychiatry Res*. 2016;**239**:12–19.
9. Odlaug BL, Kim SW, Grant JE. Quality of life and clinical severity in pathological skin picking and trichotillomania. *J Anxiety Disord*. 2010;**24**(8):823–829.
10. Nunes-Neto PR, Kohler CA, Schuch FB, et al. Food addiction: prevalence, psychopathological correlates and associations with quality of life in a large sample. *J Psychiatric Res*. 2018;**96**:145–152.
11. Lima AB, Kohler CA, Stubbs B, et al. An exploratory study of the heterogeneity of the jealousy phenomenon and its associations with affective temperaments and psychopathological dimensions in a large Brazilian sample. *J Affective Disord*. 2017;**212**:10–16.
12. Machado MO, Kohler CA, Stubbs B, et al. Skin picking disorder: prevalence, correlates, and associations with quality of life in a large sample. *CNS Spectr*. 2018;**23**(5):311–320.
13. Schwartz CE, Zhang J, Stucky BD, Michael W, Rapkin BD. Is the link between socioeconomic status and resilience mediated by reserve-building activities: mediation analysis of web-based cross-sectional data from chronic medical illness patient panels. *BMJ Open*. 2019;**9**(5):e025602.
14. Hori D, Takao S, Kawachi I, et al. Relationship between workplace social capital and suicidal ideation in the past year among employees in Japan: a cross-sectional study. *BMC Public Health*. 2019;**19**(1):919.
15. Grant JE. Impulse control disorders: a clinician's guide to understanding and treating behavioral addictions. In: *Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions*. New York, NY: W W Norton & Co; 2008:xii, 209.
16. Lawshe CH. A quantitative approach to content validity. *Personnel Psychol*. 1975;**28**(4):563–575.
17. Camara RA, Kohler CA, Frey BN, Hyphantis TN, Carvalho AF. Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life. *Rev Bras Psiquiatr*. 2017;**39**(2):140–146.
18. Angst J, Adolfsson R, Benazzi F, et al. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. *J Affective Disord*. 2005;**88**(2):217–233.
19. Soares OT, Moreno DH, Moura EC, Angst J, Moreno RA. Reliability and validity of a Brazilian version of the Hypomania Checklist (HCL-32) compared to the Mood Disorder Questionnaire (MDQ). *Rev Bras Psiquiatr*. 2010;**32**(4):416–423.
20. Carvalho AF, Takwoingi Y, Sales PM, et al. Screening for bipolar spectrum disorders: a comprehensive meta-analysis of accuracy studies. *J Affective Disord*. 2015;**172**:337–346.
21. Santos IS, Tavares BF, Munhoz TN, et al. Sensitivity and specificity of the Patient Health Questionnaire-9 (PHQ-9) among adults from the general population. *Cad Saude Publica*. 2013;**29**(8):1533–1543.
22. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;**16**(9):606–613.
23. Choi YJ, Lee WY. The prevalence of suicidal ideation and depression among primary care patients and current management in South Korea. *Int J Ment Health Syst*. 2017;**11**:18.
24. de Menezes-Gaya C, Zuairi AW, de Azevedo Marques JM, Souza RM, Loureiro SR, Crippa JA. Psychometric qualities of the Brazilian versions of the Fagerstrom Test for Nicotine Dependence and the Heaviness of Smoking Index. *Nicotine Tobacco Res*. 2009;**11**(10):1160–1165.
25. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addiction*. 1991;**86**(9):1119–1127.
26. Lima CT, Freire AC, Silva AP, Teixeira RM, Farrell M, Prince M. Concurrent and construct validity of the audit in an urban Brazilian sample. *Alcohol Alcoholism*. 2005;**40**(6):584–589.
27. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO

- Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. *Addiction*. 1993;**88**(6):791–804.
28. Osorio FL, Salum GA, Donadon MF, Forni-Dos-Santos L, Loureiro SR, Crippa JA. Psychometrics properties of early trauma inventory self report—short form (ETISR-SR) for the Brazilian context. *PLoS ONE*. 2013;**8**(10):e76337.
29. Bremner JD, Bolus R, Mayer EA. Psychometric properties of the early trauma inventory-self report. *J Nervous Ment Dis*. 2007;**195**(3):211–218.
30. Carissimi A. *Examinando fatores causais de sintomas psicológicos através do SCL-90-R em pacientes com apneia do sono grave* 2011.
31. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. *Psychol Med*. 1983;**13**(3):595–605.
32. Fleck MP, Louzada S, Xavier M, et al. Application of the Portuguese version of the abbreviated instrument of quality of life WHOQOL-bref. *Rev Saude Publica*. 2000;**34**(2):178–183.
33. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. *Psychol Med*. 1998;**28**(3):551–558.
34. Cohen J. A power primer. *Psychol Bull*. 1992;**112**(1):155–159.
35. Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. *J Clin Psychiatry*. 1991;**52**(10):415–417.
36. King RA, Zohar AH, Ratzoni G, et al. An epidemiological study of trichotillomania in Israeli adolescents. *J Am Acad Child Adolesc Psychiatry*. 1995;**34**(9):1212–1215.
37. Solley K, Turner C. Prevalence and correlates of clinically significant body-focused repetitive behaviors in a non-clinical sample. *Compr Psychiatry*. 2018;**86**:9–18.
38. Christenson GA, MacKenzie TB, Mitchell JE. Adult men and women with trichotillomania. A comparison of male and female characteristics. *Psychosomatics*. 1994;**35**(2):142–149.
39. Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. *Am J Psychiatry*. 1991;**148**(3):365–370.
40. Grant JE, Redden SA, Medeiros GC, et al. Trichotillomania and its clinical relationship to depression and anxiety. *Int J Psychiatry Clin Pract*. 2017;**21**(4):302–306.
41. Chamberlain SR, Lochner C, Stein DJ, et al. Behavioural addiction—a rising tide? *Eur Neuropsychopharmacol*. 2016;**26**(5):841–855.
42. Grant JE, Atmaca M, Fineberg NA, et al. Impulse control disorders and "behavioural addictions" in the ICD-11. *World Psychiatry*. 2014;**13**(2):125–127.
43. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. *Pharmacol Biochem Behav*. 2012;**100**(4):801–810.
44. Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. *Rev Bras Psiquiat*. 2014;**36**(2):168–175.
45. Turecki G, Brent DA. Suicide and suicidal behaviour. *Lancet*. 2016;**387**(10024):1227–1239.
46. Ozten E, Sayar GH, Eryilmaz G, Kagan G, Isik S, Karamustafalioglu O. The relationship of psychological trauma with trichotillomania and skin picking. *Neuropsychiatric Dis Treat*. 2015;**11**:1203–1210.
47. Gershuny BS, Keuthen NJ, Gentes EL, et al. Current posttraumatic stress disorder and history of trauma in trichotillomania. *J Clin Psychol*. 2006;**62**(12):1521–1529.
48. Herman JL. Trauma and recovery. New York, NY: Basic Books; 1997.
49. Hollander E, Doernberg E, Shavitt R, et al. The cost and impact of compulsivity: a research perspective. *Eur Neuropsychopharmacol*. 2016;**26**(5):800–809.